PUBLISHER: Grand View Research | PRODUCT CODE: 1375907
PUBLISHER: Grand View Research | PRODUCT CODE: 1375907
The global vaginitis therapeutics market size is expected to reach USD 6.0 billion by 2030, registering a CAGR of 8.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Supportive initiatives by government and non-government agencies to increase awareness level among women is driving the demand for vaginitis drugs. Increased consumption of alcohol is also estimated to fuel the adoption of these drugs. Around 5.3 million women in the U.S. are at risk related to health and general well-being.
Furthermore, rising R&D activities for vaginitis therapeutics is anticipated to accelerate the market growth. National Institute of Allergy and Infectious Diseases (NIAID)-funded research has discovered various important data about yeast generative behavior, which could result in new way of treatment for yeast infections. In addition, introduction of new drugs by key companies is expected to propel the market growth. For instance, in September 2017, Symbiomix Therapeutics received FDA approval for Solosec (secnidazole) for the treatment of bacterial vaginosis.